Articles and Blog
Bionumbers Index
All Indexes Updated - End January 2012
All Indexes Updated - End January 2012
January was an up-up-month for all indexes and the NASDAQ; Drug Delivery was up 6.6%, Emerging Specialty was up 8.55 and Commercial Stage Specialty was up 2.5% on a much larger base.
DDEP2011 Report
Updated - September 2011
Our DDEP2011 report focuses on Drug Delivery and goes far beyond a simple listing and analysis of product sales. DDEP 2011 analyzes a wide variety of development and commercialization parameters that impact product success. The development parameters include: clinical development times, phase transition rates, success rates, and development costs. Commercialization parameters include: sales and prescriptions, market exclusivity and sales uptake curves. More information on DDEP2011 is available.
Articles and Blog
Posted below are our most recent published articles that cover a number of issues related to the business of biopharmaceuticals in general and drug delivery in particular. Clicking on the article titles will take you to the articles. The three most recent articles are posted below and are made available when possible via links to the publishers website. Older articles are also available, most commonly in PDF format.
The blog articles are opinion pieces related to biopharma and drug delivery business issues. These articles are one-up musings or early idea sketches for future articles.
Please contact us if you have wish to discuss any of the materials or have suggestions, corrections or concerns about the materials presented.
Recent Articles and Publications
The Pharma Revolution RecalibratedPharmaceutical Executive, November 2011 Description: Josef Bossart, PhD, Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars. |
Generic DDEP Sales & Prescription Performance 2010Drug Development & Delivery, October 2011 Description: Josef Bossart, PhD, in his previous article examined the sales and prescription performance of branded DDEPs in 2010; in this issue he looks at how generic DDEPs performed in the same period. | 
DDEP Sales & Prescription Performance 2010, Hints of the FutureDrug Development & Delivery, September 2011 Description: Josef Bossart, PhD, examines some key trends that defined 2010 and tries to understand how these figures may impact business going forward. |
Numbers That Define the Business of Drug Delivery - 2011 EditionDrug Development & Delivery, June 2011 Description: Josef Bossart, PhD, believes that with the recent release of DDEP2011, it’s time to take a peek at the numbers that define the business of Drug Delivery, which provide a foundation to better plans and outcomes in the real world of drug delivery development and commercialization. |
Pharmanumbers Article Archive - A list, with links, to all Pharma related articles published by our team.
Pharmanumbers Blog
Our blog postings can be found at jobossart.com (Drug Delivery Product Strategy and Forecast Analysis by Jo Bossart and Pharmanumbers). From time-to-time we'll post links to them here.
2011-11-14: Hotel California – Pharma Style
2011-11-14: Afrezza Partnering Prospects
2011-11-14: The Pharma Revolution Recalibrated – PharmExec Article
2011-11-14: Big Pharma Partnering – Sometimes They Get it Right
2011-11-07: $5,000, $500, $50 or $5 – A Bigger Difference than You Might Think
2011-11-03: DepoMed and the $100 Million Serada Statistical Analysis Delay
2011-10-29: Adasuve – Alexza May Get What It Needs
2011-10-19: DepoMed – The Serada Conundrum
2011-10-13: Hockey, Horses and Hormones – Eugene Melnyk and Trimel
